Labcorp Launches Nationwide RNA-Based At-Home Colorectal Cancer Test
Event summary
- Labcorp has launched ColoSense®, the first FDA-approved RNA-based at-home colorectal cancer screening test, in collaboration with Geneoscopy.
- The test is now covered for eligible Medicare and Medicare Advantage beneficiaries following a CMS update to the National Coverage Determination (NCD) in June 2026.
- ColoSense uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas, with 93% sensitivity for colorectal cancer in average-risk individuals.
- The test is designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling.
The big picture
Labcorp's launch of ColoSense® aligns with broader industry trends toward at-home diagnostic solutions that improve accessibility and early detection of diseases. The FDA approval and CMS coverage signify a strategic shift in how colorectal cancer screening is integrated into routine care, potentially setting a precedent for other RNA-based diagnostic tests. With nearly 71,000 employees serving clients globally, Labcorp's move underscores the growing importance of innovative laboratory services in preventive healthcare.
What we're watching
- Market Adoption
- How the nationwide availability and Medicare coverage will affect adoption rates among eligible adults.
- Competitive Dynamics
- Whether Labcorp can sustain its market position with ColoSense amid potential competition from other diagnostic innovations.
- Regulatory Impact
- The pace at which additional commercial coverage will be secured, expanding access beyond Medicare beneficiaries.
Related topics